Goldman Sachs Endorses Braze: A Leader in AI-Powered Marketing
Money

Goldman Sachs Endorses Braze: A Leader in AI-Powered Marketing

authorBy Dave Ramsey
DateJul 05, 2026
Read Time3 min
This report details Goldman Sachs' recent positive outlook on Braze, Inc. (BRZE), an AI-powered customer engagement platform. It highlights Braze's strong market position against traditional marketing tools, its accelerating financial performance, and its innovative use of artificial intelligence to enhance customer interactions. The article also touches upon analyst ratings and future growth projections for the company.

Braze: Revolutionizing Customer Engagement with AI, Backed by Wall Street's Confidence

Unveiling Braze's Market Strength and Goldman Sachs' Optimistic Forecast

Braze, Inc. (BRZE) is gaining significant attention as a promising technology investment. Goldman Sachs recently initiated coverage with a "Buy" rating and a $34 price target. The investment bank lauded Braze's strategic advantage in capturing market share from older marketing technologies, especially as artificial intelligence intensifies the demand for advanced solutions within organizations. Goldman Sachs emphasized Braze's capability to empower marketers in crafting intricate campaigns that meet evolving customer demands, predicting the company will reach a 20% operating margin by 2029.

Analyst Perspectives: A Consensus on Braze's Promising Trajectory

Prior to Goldman Sachs' report, Citi analyst Tyler Radke also maintained a "Buy" rating on Braze, Inc. (BRZE), albeit with a slightly adjusted price target of $48 from $49. Radke's assessment followed Braze's solid earnings report, underscoring the company's consistent performance and potential for continued growth in the competitive tech landscape.

Fiscal Milestones: Braze's Accelerated Growth and AI-Driven Innovation

Braze, Inc. (BRZE) showcased impressive financial results for its fiscal first-quarter 2027. The company reported revenues of $211.0 million, marking a substantial 30.2% increase year-over-year. This achievement represents the fourth consecutive quarter of accelerated organic revenue growth. CEO Bill Magnuson attributed this success to the strong demand for Braze's AI-powered tools, including BrazeAI Operator and BrazeAI Agent Console. Furthermore, non-GAAP operating income surged to $10.5 million from $2.8 million in the prior year, and the customer base expanded to 2,713, up from 2,342. For fiscal year 2027, Braze projects revenues between $895.0 million and $899.0 million, signaling continued robust expansion.

Empowering Brands: Braze's Comprehensive Customer Engagement Ecosystem

At its core, Braze, Inc. (BRZE) specializes in fostering connections between brands and consumers globally through its sophisticated customer engagement platform. The company offers a suite of services designed to optimize interactions, including efficient data ingestion, timely online notifications, and engaging interstitial messages. Braze also plays a crucial role in helping brands systematically synchronize and transform consumer data, thereby enhancing the effectiveness of their marketing endeavors.

Strategic Investment Outlook: Beyond Braze to Overlooked AI Opportunities

While acknowledging Braze's significant investment potential, there are other AI companies that present even greater upside with potentially lower risk. Investors seeking highly undervalued AI stocks, particularly those positioned to benefit from shifting trade policies and domestic manufacturing trends, are encouraged to explore a specialized report on top short-term AI investment opportunities. Additionally, further research into stocks with high growth potential over three to ten years is recommended for those aiming to build long-term wealth.

More Articles
Money
Leerink: Altimmune an Attractive Opportunity in MASH Therapy
Leerink analyst Thomas Smith initiated coverage of Altimmune (NASDAQ:ALT) with an "Outperform" rating and a $10 price target. This follows positive 48-week results from Altimmune's IMPACT Phase 2b trial for its MASH drug candidate, pemvidutide, which demonstrated significant improvements in cardiometabolic measures and was well-tolerated. The company's dual GLP-1/glucagon receptor agonist shows promise for metabolic and liver diseases, attracting strong analyst confidence.
By Ramit SethiJul 05, 2026
Money
NICE Bolsters AI Reach with Sopra Steria's CXone Rollout and New AI Specialization Program
NICE Ltd. (NASDAQ: NICE) is expanding its artificial intelligence capabilities through strategic partnerships and platform deployments. The company recently announced that European technology firm Sopra Steria has integrated NICE's CXone platform to empower its customer service agents with advanced AI functionalities. This rollout, spanning France, Poland, and India, supports over 2,000 employees and aims to enhance customer service efficiency. Additionally, NICE launched an AI Specialization Program within its NiCE 360 Partner Program, onboarding six inaugural partners including Accenture and Deloitte, to validate and scale AI solutions across enterprises.
By Vicki RobinJul 05, 2026
Money
Understanding the Hidden Costs of SCHD ETF: Beyond the Low Fee
While SCHD boasts an attractive 0.06% expense ratio, its true costs extend far beyond this nominal figure. Investors may experience significant opportunity costs due to underperformance compared to other dividend-focused ETFs, unintended over-concentration in its top ten holdings, and unexpected tax implications from its annual reconstitution. This analysis reveals that SCHD's seemingly low fee obscures deeper financial considerations that can impact long-term portfolio growth and income stability.
By T. Harv EkerJul 05, 2026
Money
Micron Technology's Soaring Potential: A Deep Dive into its Bullish Outlook Amidst the AI Boom
Micron Technology has seen an astonishing 740% return over the past year, with some analysts forecasting its stock price could reach $1,500. This optimistic outlook is heavily influenced by the ongoing AI supercycle, which is driving unprecedented demand for Micron's memory processors. Despite potential market volatility, the company's strong profitability and expanding sales in the data center sector suggest a robust future.
By Scott PapeJul 05, 2026
Money
AI Stock Surge: Top Picks for the Second Half of 2026
The first half of 2026 has seen a significant shift in the AI sector, with memory chip companies outperforming previous market leaders. This article highlights two AI stocks, Nvidia and Meta Platforms, that are poised for substantial growth in the latter half of the year, despite recent market hesitancy and spending concerns. It delves into their current valuations, growth prospects, and strategic positioning within the evolving AI landscape, suggesting they are undervalued and set for a rebound.
By Dave RamseyJul 05, 2026